An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib With Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients With Gastric Cancer

NCT04745988 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

43

Enrollment

OTHER

Sponsor class

Conditions

Gastric Cancer

Interventions

DRUG: Lenvatinib 20mg
DRUG: Pembrolizumab
DRUG: Lenvatinib 8mg
DRUG: Docetaxel
DRUG: Oxaliplatin
DRUG: Levofolinate
DRUG: Fluorouracil

Sponsor

National Cancer Center Hospital East

Collaborators

[object Object]